A detailed history of Krensavage Asset Management, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Krensavage Asset Management, LLC holds 123,785 shares of BIIB stock, worth $21.5 Million. This represents 13.18% of its overall portfolio holdings.

Number of Shares
123,785
Previous 134,068 7.67%
Holding current value
$21.5 Million
Previous $28.9 Million 0.74%
% of portfolio
13.18%
Previous 12.82%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$190.52 - $236.72 $1.96 Million - $2.43 Million
-10,283 Reduced 7.67%
123,785 $28.7 Million
Q1 2024

May 15, 2024

SELL
$212.02 - $267.71 $5.6 Million - $7.07 Million
-26,412 Reduced 16.46%
134,068 $28.9 Million
Q3 2023

Nov 14, 2023

SELL
$253.3 - $285.89 $4.14 Million - $4.67 Million
-16,346 Reduced 9.24%
160,480 $41.2 Million
Q2 2023

Aug 11, 2023

SELL
$275.25 - $318.06 $82,575 - $95,418
-300 Reduced 0.17%
176,826 $50.4 Million
Q1 2023

May 15, 2023

BUY
$256.56 - $292.34 $31,300 - $35,665
122 Added 0.07%
177,126 $49.2 Million
Q4 2022

Feb 15, 2023

SELL
$252.44 - $306.72 $1.93 Million - $2.34 Million
-7,644 Reduced 4.14%
177,004 $49 Million
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $13.1 Million - $18.1 Million
67,400 Added 57.48%
184,648 $49.3 Million
Q2 2022

Aug 16, 2022

BUY
$187.54 - $223.02 $1.11 Million - $1.31 Million
5,895 Added 5.29%
117,248 $23.9 Million
Q1 2022

May 17, 2022

BUY
$193.77 - $244.14 $1.61 Million - $2.03 Million
8,300 Added 8.05%
111,353 $23.5 Million
Q4 2021

Feb 15, 2022

SELL
$223.92 - $287.77 $33,364 - $42,877
-149 Reduced 0.14%
103,053 $24.7 Million
Q3 2021

Nov 16, 2021

BUY
$282.99 - $369.05 $1.61 Million - $2.1 Million
5,679 Added 5.82%
103,202 $29.2 Million
Q2 2021

Aug 13, 2021

SELL
$259.0 - $414.71 $10.6 Million - $17 Million
-40,995 Reduced 29.6%
97,523 $33.8 Million
Q1 2021

May 18, 2021

BUY
$242.95 - $284.63 $121,717 - $142,599
501 Added 0.36%
138,518 $38.8 Million
Q4 2020

Feb 17, 2021

BUY
$236.26 - $355.63 $201,766 - $303,708
854 Added 0.62%
138,017 $33.8 Million
Q3 2020

Nov 17, 2020

SELL
$264.77 - $305.71 $3.77 Million - $4.36 Million
-14,257 Reduced 9.42%
137,163 $38.9 Million
Q2 2020

Aug 17, 2020

BUY
$258.66 - $342.55 $10.5 Million - $13.9 Million
40,649 Added 36.7%
151,420 $40.5 Million
Q1 2020

May 18, 2020

BUY
$268.85 - $341.04 $233,092 - $295,681
867 Added 0.79%
110,771 $35 Million
Q4 2019

Feb 18, 2020

SELL
$220.06 - $304.07 $14.7 Million - $20.3 Million
-66,806 Reduced 37.81%
109,904 $32.6 Million
Q3 2019

Nov 15, 2019

BUY
$217.44 - $243.88 $33,485 - $37,557
154 Added 0.09%
176,710 $41.1 Million
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $755,234 - $832,483
-3,444 Reduced 1.91%
176,556 $41.3 Million
Q1 2019

May 15, 2019

BUY
$216.71 - $338.96 $39 Million - $61 Million
180,000 New
180,000 $42.5 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Krensavage Asset Management, LLC Portfolio

Follow Krensavage Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Krensavage Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Krensavage Asset Management, LLC with notifications on news.